CervoMed Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held on June 8, 2026. As of the record date (April 17, 2026), there were 9,258,719 shares of common stock outstanding. A quorum was established with 6,218,593 shares (approximately 67.2%) present virtually or by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Four proposals were submitted to stockholders and all were approved:
- Proposal 1 (Director Election): Eight nominees were elected to the Board of Directors. Each nominee received a plurality of votes cast. Broker non-votes totaled 3,033,573 for all candidates.
- Proposal 2 (Auditor Ratification): Stockholders ratified the selection of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026. Votes: 6,092,751 For, 21,433 Against, 104,409 Abstain.
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation of named executive officers for the year ended December 31, 2024. Votes: 3,073,013 For, 104,221 Against, 7,786 Abstain.
- Proposal 4 (Equity Plan Amendment): Stockholders approved Amendment No. 1 to the CervoMed Inc. 2025 Equity Incentive Plan. Votes: 3,044,744 For, 132,860 Against, 7,416 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves as a disclosure of the meeting outcomes.
Investor Verification Checklist
- Verify the final composition of the Board of Directors following the election of the eight nominees.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 30, 2026, for detailed descriptions of the proposals and executive compensation data.
- Confirm the terms of Amendment No. 1 to the 2025 Equity Incentive Plan to understand potential dilution or changes to equity awards.
- Monitor subsequent filings for the company's financial results for the fiscal year ending December 31, 2026, as this 8-K contains no financial data.